QuickView for Argatroban (compound)

Summary
General Info

PubChem

PubChem Compound 152951

Name:	argatroban
PubChem Compound ID:	152951
Molecular formula:	C₂₃H₃₆N₆O₅S
Molecular weight:	508.635 g/mol
Synonyms:	121785-71-5; 21R-Argatroban; MQI-ARG-MCP; 2-Piperidinecarboxylic acid, 1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-, (2R-(1(S(R)),2alpha,4beta))-; Argatroban

DrugBank

Identification

Name:	argatroban
Name (isomeric):	DB00278
Drug Type:	small molecule
Category:	Anticoagulants, Platelet Aggregation Inhibitors
CAS number:	74863-84-6

Pharmacology

Indication:	Argatroban is indicated for prevention and treatment of thrombosis caused by heparin induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.
Pharmacology:	Argatroban is a synthetic direct thrombin inhibitor derived from L-arginine indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban does not require the co-factor antithrombin II... show more » Argatroban is a synthetic direct thrombin inhibitor derived from L-arginine indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation. Argatroban is highly selective for thrombin with an inhibitory constant (K_i) of 0.04 µM. At therapeutic concentrations, Argatroban has little or no effect on related serine proteases (trypsin, factor Xa, plasmin, and kallikrein). Argatroban is capable of inhibiting the action of both free and clot-associated thrombin. show less «
Mechanism of Action:	Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation.
Absorption:	Bioavailability is 100% (intravenous).
Protein binding:	54%
Biotransformation:	Liver via hydroxylation and aromatization of the 3-methyltetrahydroquinoline ring. Age and gender do not substantially affect the pharmacodynamic or pharmacokinetic profile of argatroban.
Route of elimination:	Argatroban is excreted primarily in the feces (65%), presumably through biliary secretion; 22% is eliminated via urine.
Half Life:	39 and 51 minutes
Clearance:	5.1 L/kg/hr [infusion doses up to 40 mcg/kg/min]
Toxicity:	Excessive bleeding
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Herbs and food with anticoagulant/antiplatelet activity. Major interactions may occur with danshen, dong quai, evening primrose oil, gingko, policosanol, willow bark

Drug interaction:

Ginkgo biloba	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
Treprostinil	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Argatroban. Monitor for increased bleeding during concomitant thearpy.

Targets

Prothrombin

Enzymes

Cytochrome P450 3A4

Cytochrome P450 3A5